NGEN.V - NervGen Pharma Corp.
| Previous Close | 1.1600 |
| Open | 1.1700 |
| Bid | 1.1900 x 0 |
| Ask | 1.2400 x 0 |
| Day's Range | 1.1700 - 1.2200 |
| 52 Week Range | 0.8000 - 3.2500 |
| Volume | 6,200 |
| Avg. Volume | 40,245 |
| Market Cap | 35.809M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.3320 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Newsfile
NervGen Pharma Provides a Corporate Update in Response to the COVID-19 Pandemic; Announces Upcoming Presentation at Solebury Trout Virtual Investor Conference on April 7th
Phase 1 Clinical Study Remains on Track for Q4 2020 Vancouver, British Columbia--(Newsfile Corp. - April 6, 2020) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today provided an update on its business in response to the COVID-19 global crisis.Paul Brennan, NervGen's President & CEO, stated, "In response to the global outbreak of COVID-19, ...
- Newsfile
NervGen Pharma Provides a Development Update on Its Lead Product NVG-291
Vancouver, British Columbia--(Newsfile Corp. - February 26, 2020) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage, today is providing an update to its development plan for its lead program, NVG-291. These changes are the result of a number of factors, including feedback from the United States Food and Drug Administration (the "FDA") on the recently ...
- Newsfile
NervGen Pharma Appoints Bill Adams as Chief Financial Officer
Vancouver, British Columbia--(Newsfile Corp. - February 24, 2020) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage, today announced the appointment of Mr. William (Bill) Adams, CPA, CA, to the position of Chief Financial Officer effective immediately. Mr. Adams replaces Mr. Robert Pilz who will continue to formally support the Company as a consultant. "Bill is ...
- Newsfile
NervGen Pharma Responds to Recent Increase in Market Activity
Vancouver, British Columbia--(Newsfile Corp. - January 13, 2020) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage, confirms that the Company's management is unaware of any undisclosed information or material change in the Company's operations that would account for the recent increase in market activity.About NervGenNervGen is restoring life's potential by creating innovative solutions for the ...
- Newsfile
NervGen Pharma Appoints Paul Brennan as President & Chief Executive Officer
Lloyd Mackenzie Appointed to the New Position of Chief Operating Officer Vancouver, British Columbia--(Newsfile Corp. - November 27, 2019) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage, today announced the appointment of Mr. Paul Brennan to the position of President & CEO effective immediately, replacing Dr. Ernest Wong who will continue to formally support the Company ...
- Newsfile
NervGen Pharma Completes Share Issuance to Drug Manufacturing Partner CSBio
Vancouver, British Columbia--(Newsfile Corp. - November 21, 2019) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage, today announced that, further to its press release dated November 18, 2019, it has issued 1,500,000 common shares (the "Common Share(s)") to its manufacturing partner, CSBio, as partial consideration for an order of NVG-291 that will be used ...
- Newsfile
NervGen Pharma Receives Investment from Drug Manufacturing Partner
CSBio Invests US$1,500,000 as Part of Manufacturing Contract for Clinical Trial Product Vancouver, British Columbia--(Newsfile Corp. - November 18, 2019) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage, today announced that it has entered into an agreement to issue 1,500,000 common shares at a price of US$1.00 (CA$1.3231 equivalent) per common share on a private ...
- Newsfile
NervGen Pharma Expands Platform into Alzheimer's Disease
NervGen Pharma's NVG-291 Compound on Track to Begin Phase 1 in Q1 2020 Vancouver, British Columbia--(Newsfile Corp. - October 28, 2019) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a regenerative medicine company dedicated to creating novel treatments for nerve damage and neurodegenerative diseases, today announced a research initiative to advance its proprietary therapeutic technology platform, currently in development for spinal cord injury and multiple sclerosis, to generate new treatments for ...
- Newsfile
NervGen Pharma Announces Clinical Development Plan for the Treatment of Nerve Damage and Neurodegenerative Diseases
NervGen Reports Results of Annual General Meeting of Shareholders Vancouver, British Columbia--(Newsfile Corp. - September 6, 2019) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today announced the clinical development strategy for its compound, NVG-291, in two lead indications: spinal cord injury and multiple sclerosis. The NVG-291 clinical development program is planned as ...
- Simply Wall St.
How Much Of NervGen Pharma Corp. (CVE:NGEN) Do Insiders Own?
Every investor in NervGen Pharma Corp. (CVE:NGEN) should be aware of the most powerful shareholder groups. Insiders...
- CNW Group
Life Science Company Live Investor Presentations Now Available for On-Demand Viewing
Individual and institutional investors as well as advisors are invited to log-on to VirtualInvestorConferences.com to view presentations NEW YORK , July 15, 2019 /CNW/ - Virtual Investor Conferences, the ...
- Newsfile
NervGen Pharma's Multiple Sclerosis Development Program Targeting Nerve Remylenation Supported by Publication of Independent Peer Reviewed Paper
Vancouver, British Columbia--(Newsfile Corp. - July 10, 2019) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today reports the publication of a new, independent study using NervGen's core Intracellular Sigma Peptide ("ISP") technology in a mouse model representative of demyelination in multiple sclerosis.The peer reviewed paper, "Modulating Proteoglycan Receptor PTPσ Using ...
- CNW Group
Life Science Company Live Investor Conference July 11th
Life science company executives will share vision and answer audience questions at VirtualInvestorConferences.com NEW YORK , July 9, 2019 /CNW/ - Virtual Investor Conferences today announced the agenda ...
- Newsfile
NervGen Amends Investor Relations Agreement
Vancouver, British Columbia--(Newsfile Corp. - July 5, 2019) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today announced the Company has agreed to amend the terms of an investor relations services agreement dated January 16, 2019 with Mr. Huitt Tracey of Vancouver, Canada. Mr. Tracey is being granted an additional ...
- Newsfile
NervGen Pharma Launches Multiple Sclerosis Program Targeting Nerve Remyelination
LeadIndication for Spinal Cord Injury Continues to Advance to Phase One Clinical Trial Vancouver, British Columbia--(Newsfile Corp. - June 26, 2019) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today announced its goal to apply its proprietary platform drug technology beyond spinal cord injury to multiple sclerosis ("MS"), another debilitating nerve damage related ...
- Newsfile
NervGen Pharma Announces Upgrade to the OTCQX Best Market in the U.S.
Vancouver, British Columbia--(Newsfile Corp. - June 10, 2019) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today announced that the Company has qualified to trade its common shares on the OTCQX® Best Market ("OTCQX"). NervGen upgraded to OTCQX from the OTCQB® Venture Market and begins trading today under the symbol "NGENF"."The upgrade ...
- Newsfile
NervGen Pharma Presenting at the 9th Annual LD Micro Invitational
Vancouver, British Columbia--(Newsfile Corp. - June 4, 2019) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) ("NervGen" or the "Company"), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage, including spinal cord and peripheral nerve injury, today announced that Ernest Wong, NervGen Pharma's President & CEO, will be presenting at the 9th Annual LD Micro Invitational on Wednesday, June 5 at 8:40AM PDT / 11:40AM EDT. In addition, ...
- ACCESSWIRE
NervGen Pharma Corp. to Present at the 9th Annual LD Micro Invitational
LOS ANGELES, CA / ACCESSWIRE / June 4, 2019 / NervGen Pharma Corp. (NGEN.V) (NGENF), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage, including spinal cord and peripheral nerve injury, today announced that it will be presenting at the 9th annual LD Micro Invitational on Wednesday, June 5 at 8:40AM PDT / 11:40AM EDT. Ernest Wong, NervGen's President & CEO, will be presenting and meeting with investors. "This year's Invitational will showcase some of the most unique names in the financial world, from early-stage start-ups to well-established names on the national exchanges," stated Chris Lahiji, LD Micro's President.
- Newsfile
NervGen Pharma Engages Torrey Hills Capital for Investor Relations
Vancouver, British Columbia--(Newsfile Corp. - June 3, 2019) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) ("NervGen" or the "Company"), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage, including spinal cord and peripheral nerve injury, today announced that it has engaged San Diego based Torrey Hills Capital, Inc. ("Torrey Hills Capital") to provide market awareness and investor relations services to the Company.Torrey Hills Capital is a ...
- Newsfile
NervGen Pharma Appoints Dr. Denis Bosc as Vice President of Manufacturing
Paul Brennan Joins NervGen Pharma as Business Advisor Vancouver, British Columbia--(Newsfile Corp. - May 30, 2019) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) ("NervGen" or the "Company"), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage, including spinal cord and peripheral nerve injury, today announced that it has appointed Denis Bosc, PhD, as the Company's Vice President, Chemistry, Manufacturing and Control (CMC). In addition, Paul Brennan has joined ...
- Newsfile
NervGen Pharma Commences Trading on OTCQB
NervGen Pharma Engages Market Maker Vancouver, British Columbia--(Newsfile Corp. - May 3, 2019) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) ("NervGen" or the "Company"), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage including spinal cord and peripheral nerve injury, today announced that in addition to trading on the TSX Venture Exchange, its common shares will commence trading today on the OTCQB Venture Market under the symbol ...
CNW GroupNervGen Pharma Corp. Opens the Market
TORONTO , May 2, 2019 /CNW/ - Bill Radvak , Executive Chairman, NervGen Pharma Corp. (NGEN), joined Tim Babcock , Managing Director, Capital Formation, TSX Venture Exchange, to open the market. NervGen ...
- Newsfile
NervGen Pharma to Ring the Opening Bell of Toronto Stock Exchange
NervGen Pharma Closes Private Placement Vancouver, British Columbia--(Newsfile Corp. - May 1, 2019) - NervGen Pharma Corp. (TSXV: NGEN) ("NervGen" or the "Company"), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage including spinal cord and peripheral nerve injury, today announced that the Company will ring the opening bell at Toronto Stock Exchange tomorrow morning to celebrate its listing on March 13, 2019."As the Company continues to broaden its ...
- Newsfile
NervGen Pharma's Patent Estate Grows with the Addition of US Patents for Its Groundbreaking Nerve Regeneration Technology
Vancouver, British Columbia--(Newsfile Corp. - April 24, 2019) - NervGen Pharma Corp. ("NervGen"), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage, announces the issuance by the U.S. Patent and Trademark Office of two new patents protecting the development and commercialization of protein tyrosine phosphatase sigma (PTPσ) targeted therapies for heart diseases and injury, and for root avulsion involving injuries into the peripheral nerve system. "The issuance of ...
- Newsfile
Amended: NervGen Pharma Increases Private Placement to $740,000
This Supersedes April 22, 2019 News Release Vancouver, British Columbia--(Newsfile Corp. - April 23, 2019) - NervGen Pharma Corp. ("NervGen" or the "Company"), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage, today announced that it has increased the amount of its non-brokered private placement announced on March 14, 2019 from $500,000 to $740,000. The Company now intends to issue 350,000 shares at $1.00 each (as before) ...
